These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25348640)

  • 21. Specialty Drugs - A Distinctly American Phenomenon.
    Naci H; Kesselheim AS
    N Engl J Med; 2020 Jun; 382(23):2179-2181. PubMed ID: 32492301
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmaceutical cost-containment policies and sustainability: recent Irish experience.
    Kenneally M; Walshe V
    Value Health; 2012; 15(2):389-93. PubMed ID: 22433772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Building on success with new fields to conquer.
    Iglehart JK
    Health Aff (Millwood); 2014 Jun; 33(6):926. PubMed ID: 24889939
    [No Abstract]   [Full Text] [Related]  

  • 24. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HHS defends expanded 340B drug discounts.
    Lee J
    Mod Healthc; 2014 Jun; 44(24):9. PubMed ID: 25137989
    [No Abstract]   [Full Text] [Related]  

  • 26. Pricing and reimbursement of pharmaceuticals in Belgium.
    Annemans L; Crott R; De Clercq H; Huybrechts M; Peys F; Robays H; Steens I; Vanschoubroek K; Winderickx P
    Pharmacoeconomics; 1997 Mar; 11(3):203-9. PubMed ID: 10165309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Critical Analysis of Obamacare: Affordable Care or Insurance for Many and Coverage for Few?
    Manchikanti L; Helm Ii S; Benyamin RM; Hirsch JA
    Pain Physician; 2017 Mar; 20(3):111-138. PubMed ID: 28339427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Will evidence ever be sufficient to resolve the challenge of cost containment?
    Caplan AL
    J Clin Oncol; 2011 May; 29(15):1946-8. PubMed ID: 21502551
    [No Abstract]   [Full Text] [Related]  

  • 31. How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.
    Conti R; Dusetzina SB; Sachs R
    Health Aff (Millwood); 2020 Mar; 39(3):445-452. PubMed ID: 32119622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
    Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
    Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient Protection and Affordable Care Act of 2010: reforming the health care reform for the new decade.
    Manchikanti L; Caraway DL; Parr AT; Fellows B; Hirsch JA
    Pain Physician; 2011; 14(1):E35-67. PubMed ID: 21267047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obamacare and Lessons Learned From the Massachusetts Experience With Healthcare Reform.
    Chiodo CP
    Foot Ankle Int; 2015 Sep; 36(9):1123-4. PubMed ID: 26330525
    [No Abstract]   [Full Text] [Related]  

  • 35. Mixed picture. Calif. proposed premiums lower than expected.
    Block J
    Mod Healthc; 2013 May; 43(21):12-3. PubMed ID: 23947096
    [No Abstract]   [Full Text] [Related]  

  • 36. Sustainable rare diseases business and drug access: no time for misconceptions.
    Rollet P; Lemoine A; Dunoyer M
    Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective healthcare cost-containment policies: A systematic review.
    Stadhouders N; Kruse F; Tanke M; Koolman X; Jeurissen P
    Health Policy; 2019 Jan; 123(1):71-79. PubMed ID: 30429060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How the ACA's Health Insurance Expansions Have Affected Out-of-Pocket Cost-Sharing and Spending on Premiums.
    Glied S; Solís-Román C; Parikh S
    Issue Brief (Commonw Fund); 2016 Sep; 28():1-16. PubMed ID: 27632806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrown a curve. CMS' actuaries: healthcare spending will continue to increase, despite reform law promises.
    Daly R
    Mod Healthc; 2011 Aug; 41(31):6-7, 1. PubMed ID: 21853565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uneven cost control implementation for US Affordable Care Act.
    Furlow B
    Lancet Oncol; 2015 Jul; 16(7):758. PubMed ID: 26095783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.